|Organic compounds -- part of the class 532-570 series patents - Monitor Patents|
USPTO Class 536 | Browse by Industry: Previous - Next | All
05/2009 | Recent | 13: Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Organic compounds -- part of the class 532-570 series May archived by USPTO category 05/09Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 05/28/2009 > patent applications in patent subcategories. archived by USPTO category
20090137787 - Janus family kinases and identification of immune modulators: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells.... Agent: Knobbe, Martens, Olson & Bear, LLP
20090137788 - Uspa1 and uspa2 antigens of moraxella catarrhalis: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these... Agent: Fulbright & Jaworski L.L.P.
20090137789 - Oligonucleotide probes: e
20090137790 - Method of capping oligonucleic acid: The present invention relates to a method for producing an oligonucleic acid derivative characterized by using a phenoxyacetic acid derivative anhydride as an acylating agent and a pyridine derivative as the acylation reaction activator, in a capping step for protecting the 5′-hydroxyl group of a ribose of an oligonucleic acid... Agent: Darby & Darby P.C.
20090137791 - Methods of attaching biological compounds to solid supports using triazine: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.... Agent: Knobbe Martens Olson & Bear LLP
20090137792 - Production of l-iduronate containing polysaccharides: The present invention provides processes for the production of polysaccharides containing the L-iduronate subunit, for example, heparin-type polysaccharides. New intermediate compounds and processes developed during the production of said polysaccharides are also presented.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20090137793 - Disaccharide compounds: Disaccharide compounds used as building blocks for making heparin and heparan sulfate oligosaccharides. Also disclosed are methods for making these disaccharide compounds.... Agent: Occhiuti Rohlicek & Tsao, LLP05/21/2009 > patent applications in patent subcategories. archived by USPTO category
20090131644 - Herpesvirus ribozymes and vectors: Hammerhead ribozymes that target components critical to HSV replication (ICP4, UL20, UL30, and UL54) were synthesized and shown to efficiently cleave target RNA encoding a portion of these components in in vitro assays. Several cloned cell lines stably expressing these ribozymes were established. HSV-mediated plaque formation was dramatically reduced in... Agent: Beusse Wolter Sanks Mora & Maire
20090131645 - Clostridial toxin derivatives able to modify peripheral sensory afferent functions: This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent... Agent: Morris Manning Martin LLP
20090131646 - Novel bag proteins and nucleic acid molecules encoding them: The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate C. elegans (BAG-1, BAG-2) and the fission yeast S. pombe (BAG-1A, BAG-1B) and the nucleic acid molecules that encode them.... Agent: Mcdermott, Will & Emery
20090131647 - Methods for detecting nucleic acid sequence variations: The invention employs an unlabeled signal primer comprising a 5′ adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3′ end of which hybridizes to the complement of the 5′ adapter sequence of the signal primer to produce a... Agent: Patton Boggs LLP
20090131648 - Rigid dendrimeric structures: The present invention provides novel dendrimers having a multimeric structure obtainable by reaction of a core molecule having an adamantoid structure with branching synthons and terminating synthons, said dendrimers immobilised on a support and a method of hybridisation which uses said dendrimers immobilised on a support.... Agent: Wenderoth, Lind & Ponack, L.L.P.
20090131649 - Method of separating small rna molecules using kosmotropic salt: Disclosed is a method of separating small RNAs of 200 nucleotides or less from larger RNAs on a solid support, using a kosmotropic salt of different concentrations.... Agent: Sughrue Mion, PLLC
20090131650 - Polynucleotide capture materials, and methods of using same: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamidoamine (PAMAM(Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding... Agent: Fish & Richardson P.C.
20090131651 - Synthesis of 2-substituted adenosines: Synthesis of 2-substituted adenosines of formula (I) using 2-nitro pentabenzoyl adenosine, or 2-nitro pentaacetyl adenosine, as intermediate is described: Formula (I) wherein R=C1-6 alkoxy (straight or branched), a phenoxy group (unsubstituted, or mono-, or di-substituted by halo, amino, CF3—, cyano, nitro, C1-4 alkyl, or C1-4 alkoxy), a benzyloxy group (unsubstituted,... Agent: Fish & Richardson PC
20090131653 - Generation of phosphorus oxychloride as by-product from phosphorus pentachloride and dmf and its use for chlorination reaction by converting into vilsmeier-haack reagent: A process is described wherein after formation of first crop of Vilsmeier-Haack reagent by reacting Phosphorus Pentachloride with N,N-dimethylformamide to form a first crop of Vilsmeier reagent as insoluble crystals, a by-product of this reaction, the Phosphorus Oxy-Chloride, reacts with N,N-dimethylformamide to give a second crop of Vilsmeier reagent. This... Agent: The Nath Law Group
20090131654 - Process for the preparation of n-acetyl-d-mannosamine monohydrate: A process is described for the preparation of N-Acetyl-D-mannosamine monohydrate of formula (I) a specific intermediate in the synthesis of N-Acetyl-neuraminic acid, that is an important starting product for the synthesis of various pharmaceutically active products.... Agent: Abelman, Frayne & Schwab05/14/2009 > patent applications in patent subcategories. archived by USPTO category
20090124793 - Corticotropin releasing factor 2 receptor agonists: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.... Agent: The Procter & Gamble Company Global Legal Department - Ip
20090124794 - Htert gene expression regulatory gene: Disclosed is a novel substance capable of regulating the expression of a telomerase reverse transcriptase gene in a cell of a mammal. A gene capable of regulating the expression of hTERT, comprising a nucleotide sequence depicted in SEQ ID No: 1 or 2. The expression of a telomerase reverse transcriptase... Agent: Pearne & Gordon LLP
20090124795 - Mitochondrial dosimeter: Mitochondrial mutations occur as a product of contact of a person with an environmental pollutant. Mitochondrial mutations are readily detectable in body fluids. Measurement of mitochondrial mutations in body fluids can be used as a dosimeter to monitor exposure to the environmental pollutant. Mitochondrial mutations can also be detected in... Agent: Banner & Witcoff, Ltd.
20090124797 - Novel synthesis of beta-nucleosides: This invention relates to a process of stereoselectively synthesizing β-nucleoside, e.g., 2′-deoxy-2,2′-difluorocytidine.... Agent: Occhiuti Rohlicek & Tsao, LLP
20090124798 - Filler for optical isomer separation: A polymer compound derivative, obtained by modifying part of the hydroxy or amino groups of a polymer compound having the hydroxy or amino groups with molecules of a compound represented by the following general formula (I): A-X—Si(Y)nR3-n (I), where A represents a reactive group which reacts with a hydroxy or... Agent: Flynn Thiel Boutell & Tanis, P.C.05/07/2009 > patent applications in patent subcategories. archived by USPTO category
20090118480 - Novel quaternary polymers: The present invention relates to novel quaternized polymers, especially of chitin/chitosan type, and to carbohydrate polymers carrying quaternized ammonium groups, especially piperazinium groups. Such polymers are characterized i.a. by improved solubility characteristics.... Agent: Buchanan, Ingersoll & Rooney PC
20090118482 - Compounds and methods for labeling oligonucleotides: e
20090118481 - High affinity nucleic acid ligands to lectins: This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands. This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the... Agent: Swanson & Bratschun, L.L.C.
20090118484 - Formation of novel nucleic acid complexes and detection thereof: This invention relates to a process and system to amplify and detect recombinational non-reciprocal cross-over reactions between homologous nucleic acid molecules without the assistance from a protein factor. The result of a chain reaction of non-reciprocal cross-overs is stoichiometrical formation of nucleic acid conglomerate complex that binds significantly more ethidium... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC
20090118483 - Light-driven energy generation using proteorhodopsin: A light-driven energy generation system using proteorhodopsin is provided. The system includes a light source, a host with a correctly folded, integrated proteorhodopsin protein, a source of retinal, and a mediator. The source of retinal binds covalently to the integrated proteorhodopsin protein, thereby creating a light absorbing pigment. Illumination of... Agent: Lumen Patent Firm
20090118485 - Oligonucleotides and analogs labeled with energy transfer dyes: Novel linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye are provided. These linkers faciliate the efficient transfer of energy between a donor and acceptor dye in an energy transfer dye. One of these linkers for linking a donor dye to an acceptor... Agent: Dechert LLP
20090118486 - Uspa1 and uspa2 antigens of moraxella catarrhalis: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these... Agent: Fulbright & Jaworski L.L.P.
20090118487 - P-cadherin antibodies: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates... Agent: Pfizer Inc
20090118488 - High throughput genome sequencing on dna arrays: The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences using adaptors interspersed in target polynucleotides. The sequence information can be new, e.g. sequencing unknown nucleic acids, re-sequencing, or genotyping. The invention preferably includes methods for inserting a plurality of adaptors at spaced... Agent: Morgan, Lewis & Bockius, LLP
20090118490 - Primer for nucleic acid detection: This application provides universal labeled primers for detection and amplification of nucleic acid molecules. These universal primers can be attached to the 5′-end of a target sequence-specific primer. In particular examples, the universal primer includes a labeled nucleotide flanked on both sides a nucleotide whose complement nucleotides changes a detectable... Agent: Klarquist Sparkman, LLP
20090118489 - Sirna targeting nucleoporin 62kda (nup62): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP
20090118491 - Stable salt of 3'-phosphoadenosine 5'-phosphosulfate: f
20090118492 - Method for making inclusion complex: There is provided batch methods of making cyclopropene complex involving mixture comprising (i) one or more molecular encapsulating agent and (ii) solvent, wherein the ratio of the amount of said (i) to the amount of said (ii) is higher than the solubility of said molecular encapsulating agent in said solvent.... Agent: Rohm And Haas Company Patent Department
20090118493 - Process for purification of trichlorogalactosucrose based on direct extraction in organic solvent from reaction mixture followed by evaporative removal of solvent: A process of azeotropic removal of dimethylformamide, abbreviated as DMF, from a process stream containing DMF requiring its removal, is described wherein the said Process Stream being obtained in a process for preparation of 4,1′,6′ trichlorogalactosucrose, abbreviated as TGS, or TGS-6-ester including TGS-6-acetate or TGS-6-benzoate, comprising steps of (a) evaporation... Agent: The Nath Law Group
20090118494 - Solid acid catalyzed hydrolysis of cellulosic materials: Provided are methods for the solubilization of cellulose into soluble sugars without the need for high temperatures, high pressures, strong acid solutions, and/or added water. The produced sugars can be fermented into ethanol. In one embodiment, the method comprises contacting a cellulose-containing material with a solid acid material and agitating... Agent: Timothy H. Van DykePrevious industry: Organic compounds -- part of the class 532-570 series
Next industry: Organic compounds -- part of the class 532-570 series
RSS FEED for 20130613:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Organic compounds -- part of the class 532-570 series patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Organic compounds -- part of the class 532-570 series patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Organic compounds -- part of the class 532-570 series patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 0.25077 seconds